Cargando…

Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE

BACKGROUND: STRIVE is a multicenter, observational, open-label, single-arm study of natalizumab in anti–JC virus (JCV) seronegative patients with early relapsing-remitting multiple sclerosis (RRMS). The objective of this prespecified 2-year interim analysis was to determine the effectiveness of nata...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perumal, Jai, Fox, Robert J., Balabanov, Roumen, Balcer, Laura J., Galetta, Steven, Makh, Shavy, Santra, Sourav, Hotermans, Christophe, Lee, Lily
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555913/ https://www.ncbi.nlm.nih.gov/pubmed/31176355 http://dx.doi.org/10.1186/s12883-019-1337-z

Ejemplares similares

Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing–Remitting Multiple Sclerosis: STRIVE Data Analysis
por: Perumal, Jai, et al.
Publicado: (2023)

Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
por: Perumal, Jai, et al.
Publicado: (2021)

Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
por: Perumal, Jai, et al.
Publicado: (2021)

Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study
por: Perumal, Jai, et al.
Publicado: (2022)

Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study
por: Perumal, Jai, et al.
Publicado: (2023)

Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis
por: Gudesblatt, Mark, et al.
Publicado: (2018)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results
por: Olshansky, Brian, et al.
Publicado: (2020)

Treatment of natalizumab‐associated PML with filgrastim
por: Stefoski, Dusan, et al.
Publicado: (2019)

Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM
por: Voloshyna, N, et al.
Publicado: (2015)

Vision in a Phase 3 Trial of Natalizumab for Multiple Sclerosis: Relation to Disability and Quality of Life
por: Chahin, Salim, et al.
Publicado: (2015)

Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021)

Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results
por: Brunner, Hermine I., et al.
Publicado: (2020)

Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
por: Butzkueven, Helmut, et al.
Publicado: (2020)

Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
por: Alroughani, R., et al.
Publicado: (2013)

Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis
por: Graves, Jennifer, et al.
Publicado: (2013)

A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis
por: Trojano, Maria, et al.
Publicado: (2021)

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
por: Kappos, Ludwig, et al.
Publicado: (2013)

Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism
por: Ramos-Cejudo, Jaime, et al.
Publicado: (2011)

Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
por: Gatzonis, Stylianos, et al.
Publicado: (2009)

Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis
por: Cadavid, Diego, et al.
Publicado: (2013)

Impact of Natalizumab Treatment on Fatigue, Mood, and Aspects of Cognition in Relapsing–Remitting Multiple Sclerosis
por: Kunkel, Annett, et al.
Publicado: (2015)

Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis
por: McManus, Eileen J., et al.
Publicado: (2022)

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
por: Rezaee, Mehdi, et al.
Publicado: (2022)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Permeability of the blood–brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing–remitting multiple sclerosis
por: Cramer, Stig P., et al.
Publicado: (2018)

Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan
por: Saida, Takahiko, et al.
Publicado: (2017)

Strive
por: Amyx, Scott
Publicado: (2018)

Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
por: Planas, Raquel, et al.
Publicado: (2014)

Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
por: Grahl, S., et al.
Publicado: (2021)

Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis
por: Reardon, Jennifer, et al.
Publicado: (2013)

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
por: Furneri, Gianluca, et al.
Publicado: (2019)

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
por: Hernández-Preciado, Martha Rocio, et al.
Publicado: (2022)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
por: Alharbi, Mansour A., et al.
Publicado: (2023)

Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies
por: Gold, Ralf, et al.
Publicado: (2016)

Striving for precision
por: Cirilli, Manuela
Publicado: (2013)

Striving to be the best.
por: Nicholas, D
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_raoul0dqh7n8ngddr5o9ug7bh9